BLB8, an antiviral protein from Brevibacillus laterosporus strain B8, inhibits Tobacco mosaic virus infection by triggering immune response in tobacco.

BACKGROUND

Tobacco mosaic virus (TMV) is one of destructive plant viruses, causing serious economic losses in the world. Using antiviral proteins or elicitors to inhibit viral infection or promote plant immunity is one of the efficient strategies against TMV. Our previous study identified that the fermentation broth of Brevibacillus laterosporus strain B8 showed strong antiviral activity against TMV. However, the active antiviral ingredient is still unclear.

RESULTS

Here, BLB8 (B. laterosporus strain B8 protein, BLB8), an antiviral protein from B. laterosporus strain B8 was isolated and characterized. BLB8 showed protective, inactive and curative effects against TMV, and the inhibition rate reached up to 63%, 83% and 55%, respectively. BLB8 infiltrated around the infection site of the recombinant virus TMV-GFP inhibited the systemic extend and movement of TMV. Pretreatment of the bottom leaves with BLB8 inhibited the spread and accumulation of TMV in upper systemic leaves. Furthermore, BLB8 caused hypersensitive response (HR) in a dose-dependent way, promoted H O accumulation, and induced the expression of defense-relative genes in Nicotiana benthamiana.

CONCLUSION

The antiviral protein BLB8 from B. laterosporus strain B8 effectively inhibits TMV infection in inactivation, protective and curative effects through triggering plant immunity in tobacco. Therefore, the present study provides a new antiviral agent for prevention and control of viral disease. © 2021 Society of Chemical Industry.